Management Team 2017-08-30T13:36:16+00:00

Management Team

Joe Victor
Chief Executive Officer

Joe Victor serves on the Board of Directors at Rarecyte and has been a Venture Partner with 5AM Ventures since 2016. Prior to his joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.), and Applied Precision Inc (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy, Precision Nanosystems and Purigen Biosystems as well as on the Boards of Glencoe Software, and RareCyte. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets.  Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Ron Seubert
Chief Technology Officer

Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.

Eric Kaldjian MD
Chief Medical Officer

Eric directs the scientific and medical applications of RareCyte technology. Eric earned his MD and trained in pathology at the University of Michigan. He was a research fellow at the National Cancer Institute and is certified by the American Board of Pathology. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. Eric’s pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.

Evan Castiglia
Chief Business Officer

Evan is the Chief Business Officer at RareCyte. Previously, he was a portfolio manager for Isis Innovation Ltd. His efforts focused on leading numerous technology commercialization and intellectual property projects based on cutting edge academic research. Prior to his time at Oxford, Evan was the Director of Business Development at the Institute for Systems Medicine Planning Authority in Washington State. He earned his bachelor’s degree from Gonzaga University and his MBA from the University of Oxford.

Steve Reese
Senior VP,  Engineering and Operations

Steve Reese comes to Rarecyte from his previous role as Principal Systems Engineer within the Genomics and Cellular Research division of GE Life Sciences. He has been involved with guiding the development of more than 20 automated fluorescent imaging systems during his 25 years with Applied Precision and GE. Yale trained as an Electrical Engineer, he has focused his attention on how to optimize system design and lead teams from problem definition through invention, design, and product execution. In recent years he has been helping to optimize the integration of the Cellular Analysis team into the larger GE Life Sciences business.

Interested in learning more?

Complete the form below and we will get in touch with you to discuss any questions you may have about the company, the products or applications of RareCyte technology.